• 1
    Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 2343.
  • 2
    Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96: 51323.
  • 3
    Raul Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazar-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998; 29: 25962.
  • 4
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido ED, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 212131.
  • 5
    Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 54957.
  • 6
    Fahy BG, Sheehy AM, Coursin DB. Glucose control in the intensive care unit. Crit Care Med 2009; 37: 176976.
  • 7
    Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 93848.
  • 8
    Basi S, Pupim LB, Simmons EM, Sezer MT, Shyr Y, Freedman S, et al. Insulin resistance in critically ill patients with acute renal failure. Am J Physiol Renal Physiol 2005; 289: F25964.
  • 9
    Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med 1976; 294: 73945.
  • 10
    Baldwin D Jr, Winston E, Hoshizaki RJ, Garland JT, Baldwin D Sr, Holcomb HH, et al. Insulin-resistant diabetes with insulin receptor autoantibodies in a male patient without acanthosis nigricans. Diabetes Care 1979; 2: 2757.
  • 11
    Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81: 87100.
  • 12
    Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum. In: MazzaferiE, editor. Advances in endocrinology and metabolism. Vol. 6. St. Louis: Mosby-Year Book; 1995. p. 193232.
  • 13
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 14
    Semple RK, Halberg NH, Burling K, Soos MA, Schraw T, Luan J, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007; 56: 17127.
  • 15
    Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P, et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008; 31: 9779.
  • 16
    Fareau GG, Maldonado M, Oral E, Balasubramanyam A. Regression of acanthosis nigricans correlates with disappearance of anti-insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome. Metabolism 2007; 56: 6705.
  • 17
    Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, et al. Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab 2010; 95: 36417.
  • 18
    Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE. A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 83540.
  • 19
    Tran HA, Reeves GE. Treatment of type B insulin resistance with immunoglobulin: novel use of an old therapy [letter]. Med J Aust 2009; 190: 168.
  • 20
    Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52: 1695700.
  • 21
    Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine (Baltimore) 2009; 88: 14153.
  • 22
    Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, et al. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 1982; 307: 14226.
  • 23
    Kahn CR, Baird K, Filier JS, Jarrett DB. Effects of autoantibodies to the insulin receptor on isolated adipocytes: studies of insulin binding and insulin action. J Clin Invest 1977; 60: 1094106.
  • 24
    Di Paolo S, Giorgino R. Insulin resistance and hypoglycemia in a patient with systemic lupus erythematosus: description of antiinsulin receptor antibodies that enhance insulin binding and inhibit insulin action. J Clin Endocrinol Metab 1991; 73: 6507.
  • 25
    Flier JS, Bar RS, Muggeo M, Kahn CR, Roth J, Gorden P. The evolving clinical course of patients with insulin receptor autoantibodies: spontaneous remission or receptor proliferation with hypoglycemia. J Clin Endocrinol Metab 1978; 47: 98595.
  • 26
    Sato N, Ohsawa I, Takagi M, Gohda T, Horikoshi S, Shirato I, et al. Type B insulin resistance syndrome with systemic lupus erythematosus. Clin Nephrol 2010; 73: 15762.
  • 27
    Nagayama Y, Morita H, Komukai D, Watanabe S, Yoshimura A. Type B insulin resistance syndrome induced by increased activity of systemic lupus erythematosus in a hemodialysis patient. Clin Nephrol 2008; 69: 1304.